Edwards Lifesciences jumps after strong Q2 growth and higher 2026 sales outlook

Edwards Lifesciences (EW) is up 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst was a strong second-quarter report that showed double-digit revenue growth and higher full-year sales guidance. Investors also appeared to respond well to continued momentum in the company’s core TAVR franchise and improving expectations for its transcatheter mitral and tricuspid therapies.

Details:

Second-quarter sales rose 13.6% year over year to about $1.74 billion, with constant-currency growth of 12.5%.

TAVR sales climbed 11.3% to roughly $1.26 billion, helped by procedural growth, durable clinical evidence around the SAPIEN platform, and a favorable comparison against a competitor’s prior-year market exit.

The company lifted its 2026 constant-currency sales growth outlook to 10% to 11% from 9% to 11%, and also raised TAVR growth guidance to 8% to 9% from 7% to 9%.

TMTT sales reached about $195.9 million in the quarter, and management increased its 2026 TMTT sales outlook to $760 million to $780 million while keeping adjusted EPS guidance unchanged despite tax headwinds.

Sources:

Edwards Lifesciences, StreetInsider, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EW Insider Trading Activity

$EW insiders have traded $EW stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 7 sales selling 99,133 shares for an estimated $8,277,433.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 4 sales selling 26,000 shares for an estimated $2,144,440.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 3 sales selling 22,953 shares for an estimated $1,765,723.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 8 sales selling 5,934 shares for an estimated $503,333.
DAVEEN CHOPRA (CVP, TMTT & Surgical) sold 1,500 shares for an estimated $126,905
ANDREW M. DAHL (SVP, Corporate Controller) sold 567 shares for an estimated $48,852

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive EW Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$EW Hedge Fund Activity

We have seen 528 institutional investors add shares of $EW stock to their portfolio, and 541 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 5,079,892 shares (+65.7%) to their portfolio in Q1 2026, for an estimated $406,797,751
MILLENNIUM MANAGEMENT LLC removed 4,284,117 shares (-70.5%) from their portfolio in Q1 2026, for an estimated $343,072,089
ARTISAN PARTNERS LIMITED PARTNERSHIP added 4,034,429 shares (+345.8%) to their portfolio in Q1 2026, for an estimated $323,077,074
MARSHALL WACE, LLP removed 3,929,250 shares (-66.3%) from their portfolio in Q1 2026, for an estimated $314,654,340
BANK OF AMERICA CORP /DE/ added 2,212,208 shares (+132.4%) to their portfolio in Q1 2026, for an estimated $177,153,616
FMR LLC removed 2,078,777 shares (-12.5%) from their portfolio in Q1 2026, for an estimated $166,468,462
NEUBERGER BERMAN GROUP LLC added 2,021,413 shares (+614.8%) to their portfolio in Q1 2026, for an estimated $161,874,753

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$EW Government Contracts

We have seen $27,358,165 of award payments to $EW over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS: $238,000
CUSTOM SURGICAL IMPLANTS: $204,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$EW Congressional Stock Trading

Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$EW Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $EW, check out Quiver Quantitative's $EW forecast page.

$EW Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 13 analysts offer price targets for $EW in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $110.0 on 07/08/2026
Vijay Kumar from Evercore ISI Group set a target price of $100.0 on 07/06/2026
Marie Thibault from BTIG set a target price of $110.0 on 06/30/2026
Shagun Singh from RBC Capital set a target price of $100.0 on 06/16/2026
Joshua Jennings from TD Cowen set a target price of $104.0 on 06/02/2026
Matt Miksic from Barclays set a target price of $110.0 on 04/27/2026
William Plovanic from Canaccord Genuity set a target price of $85.0 on 04/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.